PRKG1 and renal carcinoma: For example, PDE5 inhibition activates PKG, which reduces cyclin D1 (a cell cycle promoter) and elevates p21 (a cell cycle inhibitor), leading to apoptosis and suppressed proliferation in renal cancer cells [84].